Healthcare Dec 30, 2021 08:58 AM (GMT+8) · EqualOcean
On December 23, 2021 and December 28, 2021, jdb175 tablets and jdb153, a class of small molecule innovative drugs independently developed by Chengdu Jiabao Yaoyin Pharmaceutical Technology Co., Ltd., received the drug clinical trial approval notice approved and issued by the State Drug Administration respectively. The approved indications were diffuse large B-cell lymphoma (DLBCL) and advanced solid tumor respectively.